
==== Front
Mol Psychiatry
Mol Psychiatry
Molecular Psychiatry
1359-4184
1476-5578
Nature Publishing Group UK London

38519640
2529
10.1038/s41380-024-02529-1
Article
Genetic contribution to microglial activation in schizophrenia
http://orcid.org/0000-0002-1646-9992
Koskuvi Marja 12
http://orcid.org/0000-0002-8880-9909
Pörsti Elina 1
Hewitt Tristen 1
Räsänen Noora 1
Wu Ying-Chieh 1
Trontti Kalevi 134
http://orcid.org/0000-0001-5368-6788
McQuade Amanda 567
Kalyanaraman Shringaa 1
Ojansuu Ilkka 8
Vaurio Olli 8
http://orcid.org/0000-0002-5632-3154
Cannon Tyrone D. 9
Lönnqvist Jouko 1011
http://orcid.org/0000-0001-9407-4905
Therman Sebastian 10
http://orcid.org/0000-0001-7167-0990
Suvisaari Jaana 10
http://orcid.org/0000-0002-3716-2455
Kaprio Jaakko 12
http://orcid.org/0000-0002-7770-7157
Blurton-Jones Mathew 567
http://orcid.org/0000-0002-5990-7892
Hovatta Iiris 134
http://orcid.org/0000-0002-7244-145X
Lähteenvuo Markku 8
Rolova Taisia 1
http://orcid.org/0000-0002-5055-9414
Lehtonen Šárka 113
Tiihonen Jari 1814
http://orcid.org/0000-0001-6559-1153
Koistinaho Jari jari.koistinaho@helsinki.fi

115
1 https://ror.org/040af2s02 grid.7737.4 0000 0004 0410 2071 Neuroscience Center, University of Helsinki, Helsinki, Finland
2 https://ror.org/056d84691 grid.4714.6 0000 0004 1937 0626 Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden
3 https://ror.org/040af2s02 grid.7737.4 0000 0004 0410 2071 SleepWell Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland
4 https://ror.org/040af2s02 grid.7737.4 0000 0004 0410 2071 Department of Psychology and Logopedics, University of Helsinki, Helsinki, Finland
5 https://ror.org/04gyf1771 grid.266093.8 0000 0001 0668 7243 Department of Neurobiology & Behavior, UC Irvine, Irvine, CA USA
6 https://ror.org/04gyf1771 grid.266093.8 0000 0001 0668 7243 Sue and Bill Gross Stem Cell Research Center, UC Irvine, Irvine, CA USA
7 https://ror.org/04gyf1771 grid.266093.8 0000 0001 0668 7243 Institute for Memory Impairments and Neurological Disorders, UC Irvine, Irvine, CA USA
8 grid.9668.1 0000 0001 0726 2490 Department of Forensic Psychiatry, University of Eastern Finland, Niuvanniemi Hospital, Kuopio, Finland
9 https://ror.org/03v76x132 grid.47100.32 0000 0004 1936 8710 Department of Psychology and Psychiatry, Yale University, New Haven, CT USA
10 grid.14758.3f 0000 0001 1013 0499 Mental Health Unit, Department of Public Health Solutions, National Institute for Health and Welfare, Helsinki, Finland
11 https://ror.org/040af2s02 grid.7737.4 0000 0004 0410 2071 Department of Psychiatry, University of Helsinki, Helsinki, Finland
12 grid.7737.4 0000 0004 0410 2071 Institute for Molecular Medicine FIMM, University of Helsinki, Helsinki, Finland
13 https://ror.org/00cyydd11 grid.9668.1 0000 0001 0726 2490 A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland
14 https://ror.org/056d84691 grid.4714.6 0000 0004 1937 0626 Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden
15 https://ror.org/040af2s02 grid.7737.4 0000 0004 0410 2071 Drug Research Program, Division of Pharmacology and Pharmacotherapy, University of Helsinki, Helsinki, Finland
22 3 2024
22 3 2024
2024
29 9 26222633
20 8 2022
6 3 2024
13 3 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by/4.0/ Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Several lines of evidence indicate the involvement of neuroinflammatory processes in the pathophysiology of schizophrenia (SCZ). Microglia are brain resident immune cells responding toward invading pathogens and injury-related products, and additionally, have a critical role in improving neurogenesis and synaptic functions. Aberrant activation of microglia in SCZ is one of the leading hypotheses for disease pathogenesis, but due to the lack of proper human cell models, the role of microglia in SCZ is not well studied. We used monozygotic twins discordant for SCZ and healthy individuals to generate human induced pluripotent stem cell-derived microglia to assess the transcriptional and functional differences in microglia between healthy controls, affected twins and unaffected twins. The microglia from affected twins had increased expression of several common inflammation-related genes compared to healthy individuals. Microglia from affected twins had also reduced response to interleukin 1 beta (IL1β) treatment, but no significant differences in migration or phagocytotic activity. Ingenuity Pathway Analysis (IPA) showed abnormalities related to extracellular matrix signaling. RNA sequencing predicted downregulation of extracellular matrix structure constituent Gene Ontology (GO) terms and hepatic fibrosis pathway activation that were shared by microglia of both affected and unaffected twins, but the upregulation of major histocompatibility complex (MHC) class II receptors was observed only in affected twin microglia. Also, the microglia of affected twins had heterogeneous response to clozapine, minocycline, and sulforaphane treatments. Overall, despite the increased expression of inflammatory genes, we observed no clear functional signs of hyperactivation in microglia from patients with SCZ. We conclude that microglia of the patients with SCZ have gene expression aberrations related to inflammation response and extracellular matrix without contributing to increased microglial activation.

Subject terms

Neuroscience
Stem cells
https://doi.org/10.13039/501100002341 Academy of Finland (Suomen Akatemia) 334525 336823 Kaprio Jaakko Koistinaho Jari Sigrid Juselius Foundation Business Finlandissue-copyright-statement© Springer Nature Limited 2024
==== Body
pmcIntroduction

Neuroinflammation is a pathophysiological process involved in various neurological diseases. There is increasing evidence that dysregulation of neuroinflammation and immune response is also associated with neurodevelopmental disorders, including schizophrenia (SCZ) [1, 2]. Microglia are brain resident macrophages indispensable for innate immune system activation and inflammation as a response against invading pathogens or injury-induced products to protect neurons and other glial cells from damage. Although the exact etiology of SCZ remains largely unknown, it is a complex disorder that is thought to develop as the result of the interaction between genetic changes and environmental factors initiated already during embryonal development and continuing through childhood to adolescence and early adulthood [3]. During embryonic development microglia support neurogenesis and modify synaptic network by synaptic pruning in early childhood and adulthood.

Patients with SCZ have upregulation of various markers of neuroinflammation, which has led to the theory of prolonged microglial hyperactivation as a significant contributory factor in SCZ [4]. Postmortem studies have revealed microglial activation in patients with SCZ, detected as increased microglial density based on ionized calcium-binding adapter molecule 1 (IBA1), major histocompatibility complex (MHC) class II, and cluster of differentiation 68 (CD68) immunoreactive cells [5–7]. Consistently, there is evidence for elevated levels of pro-inflammatory cytokines interleukin 6 (IL6), tumor necrosis factor alpha (TNFα), interferon (IFN), and interleukin 1 beta (IL1β) in blood and brain of patients with SCZ [1, 6, 8]. The extended MHC locus has the strongest genetic association with SCZ known so far [9]. The region contains several innate and adaptive immune system related genes, e.g., polymorphic and polygenic antigen-recognition human leukocyte antigen (HLA) genes. Due to high MHC locus polymorphism and its involvement in several autoimmune and infectious disorders, it has been hard to locate SCZ-associated genetic variants on this region [10]. Without microglia-specific genetic risk factors, the availability of experimental models to test the impact of SCZ-related microglial function is limited, and the results have been inconclusive.

As the previous studies have suggested hyperactive phenotype in microglia in patients with SCZ, we focused on this study especially on sensitivity to inflammatory stimuli and immune activation. We also studied whether the antipsychotic drug clozapine and two other compounds, minocycline and sulforaphane, have the potential to modify the functions of patient-derived microglia. Clozapine is the most common atypical antipsychotic drug used to treat treatment-resistant SCZ. Minocycline is an antibiotic drug, which has been shown to inhibit microglial activation and synaptic pruning, and thus holds potential for alternative treatment for SCZ [11–14]. Sulforaphane is an antioxidant, which can modulate inflammation-related depression-like behavior in rodents [15, 16]. Clozapine and minocycline have multiple targets, which are not all well-known, while sulforaphane mainly induces NF-E2-related factor-2 (NRF2) activation. Even though it is not completely known how these compounds affect inflammation, previous studies have shown that all three of them can protect cells from LPS-induced immune activation potentially suppressing nuclear factor kappa B (NF-κB) pathway activation [15, 17, 18]. NF-κB is a critical regulator of immune responses and controls the expression of various pro-inflammatory cytokines and acute phase proteins that are increased in the brain in people with SCZ.

We chose to use human induced pluripotent stem cell (hiPSC) derived cell models. We generated hiPSC-derived microglia-like cells (iMGLs) from our well-characterized monozygotic twins discordant for SCZ, i.e., cases with schizophrenia diagnosis and their healthy twins, and unrelated healthy controls, to assess the genetic contribution to differences (1) between affected and unaffected twins and (2) between twins and healthy controls in microglial gene expression and functions. Three of the twin pairs were females and two were males. Similarly, we recruited three female and two male un-related healthy volunteers without history of psychiatric disorders as healthy controls. By using RNA sequencing we show dysregulation of commonly used pan-microglia genes and inflammation-related genes (AIF1, HLA-DRA, and IL1β) in affected twin microglia. While global gene expression profile was downregulated in both twins compared to healthy individuals, upregulation of 22.6% of the genes was seen only in clinical SCZ cases. Pathways related to extracellular matrix signaling were consistently aberrant in microglia of both affected and unaffected twin. Our test to rescue the expressional changes with applying clozapine, minocycline or sulforaphane gave heterogeneous response in affected twin microglia.

Materials and methods

Patient iPSC lines

hiPSCs were generated and characterized in previous study by Tiihonen et al. [19]. Supplementary Tables 1 and 2 summarize the patient cohort and to which experiments they were included. Informed consent was obtained from all participants and all procedures were approved by the Ethics Committee of the Helsinki University Hospital District. Patient iPSCs were cultured in E8 medium (Gibco) on Matrigel (Corning) and splitted 1–2 times a week with 0.5 mM EDTA (Invitrogen) and tested negative for mycoplasma in Neural iPSC (NIPS) unit at the University of Helsinki. hiPSCs from passages 13–25 were used. The used reagents are listed in Supplementary Table 3.

Microglia differentiation

We used a protocol adapted from McQuade et al. [20] for hiPSC-microglia differentiation. Briefly, hiPSCs were first differentiated to hematopoietic stem cells (HPCs) with StemDiff Hematopoietic kit (StemCell Technologies) according the manufacturer’s instructions. First, hiPSC colonies were de-attached with ReLeSR (StemCell Technologies) and about 20–30 aggregates were seeded per a Matrigel coated 6-well plate in E8 medium with 10 µM ROCK inhibitor (Y-27632, Sigma). On the following day, the StemDiff medium was added onto the wells with well-distributed hiPSC-colonies. The medium was changed every other day 11–13 days until HPCs appeared. Non-adherent HPCs were collected, and 100,000–200,000 cells per well were seeded onto Matrigel-coated well on a 6-well plate in iMGL Base medium consisting of DMEM/F12 (Gibco), 2% ITS-G, 2% B27, 2 mM Glutamax, 1% NEAA, 0.5% N2, 0.5% Penstrep (all from Invitrogen), 5 µg/ml insulin (Sigma) and 400 µM Monothioglycerol (Sigma). In total, 100 ng/ml IL34 (PeproTech), 50 ng/ml TGFβ-1 (PeproTech) and 25 ng/ml M-CSF (Peprotech) were added prior use (= iMGL differentiation medium) and 1 ml of fresh medium was added every other day for 21–26 days. After the first 10–14 days of the differentiation, excess media were collected from the wells leaving only 1 ml on top of the cells. The media were centrifuged 300 × g for 4 min to collect the floating microglial precursors that were subsequently replated. To maturate the microglia, the cells were kept for three more days in iMGL maturation medium (iMGL differentiation medium + 100 ng/ml CX3CL1 (PeproTech) and 100 µg/ml CD200 (Biolegend)).

Drug treatments

The hiPSC-microglia or hiPSC-macrophages were first replated depending on the application and matured for two days. Subsequently, the drugs were added for 24 h in the same medium in the final concentration of 10 µM clozapine (Sigma), 10 µM minocycline (Sigma) or 5 µM D,L-Sulforaphane (Santa Cruz). For the drug studies on LPS-induced inflammation, cells were pre-treated with clozapine, minocycline or sulforaphane for 1 h before adding LPS (Sigma, 100 ng/ml) for 24 h in iMGL maturation medium.

Results

Expression of common homeostatic markers of human iMGLs was affected by SCZ

We used a previously established protocol to generate human iMGLs in 40 days [20] (Fig. 1a). The generated iMGLs had a ramified morphology and expressed pan-macrophage marker IBA1, and microglia-specific markers TREM2, P2RY12 and CX3CR1 (Fig. 1b and Supplementary Fig. 1). iMGLs also upregulated macrophage- and microglia-related genes compared to their intermediate progenitors (hematopoietic progenitor cells, HPCs) and separately generated hiPSC-macrophages (iMφ) (Fig. 1c and Supplementary Fig. 2a). iMGLs responded to 24-h LPS treatment by significant reduction of ITGAM, TREM2 and P2RY12 gene expression (p = 0.029 in all, Mann–Whitney test). No significant batch differences were discovered (Supplementary Fig. 2b).Fig. 1 Characterization of human iMGLs derived from monozygotic twins discordant for SCZ.

a Timeline for iMGL differentiation. Scale bar 50 µm in all. Generated iMGLs expressed (b) on protein level pan-macrophage marker IBA1, and microglia-specific markers P2Y12, TREM2 and CX3CR1 (nuclei on blue, scale bar 50 µm), and (c) on transcriptomic level AIF1 (IBA1; H(3) = 10.08, p = 0.0035), ITGAM (CD11b; H(3) = 10.93, p = 0.001; HPC vs. iMGL U = 0, p = 0.0286; iMGL vs. iMGL + LPS U = 0, p = 0.0286), P2RY12 (H(3) = 8.717, p = 0.014; HPC vs. iMGL U = 0, p = 0.0286; iMGL vs. iMGL + LPS U = 0, p = 0.0286) and TREM2 (H(3) = 9.175, p = 0.009; HPC vs. iMGL U = 0, p = 0.0286; iMGL vs. iMGL + LPS U = 0, p = 0.0286). Kruskal–Wallis test, Mann–Whitney test, n = 3–4 CTRL lines. d Illustration of patient cohort created with BioRender. e RNA expression of AIF1, TREM2, PTPRC (CD45) and TMEM119 based on bulk RNA sequencing. CTRL healthy individuals, ST affected twin, HT healthy twin, HPC hematopoietic stem cell, iMφ hiPSC-macrophage, iMGL hiPSC-microglia like cell, iMGL + LPS LPS-treated iMGL.

We generated iMGLs from a total of five monozygotic twin pairs, where one twin was diagnosed with SCZ (ST) and the other twin was healthy (HT), but had thus a high genetic risk to develop SCZ. Additionally, we generated iMGLs from five non-related healthy individuals (CTRL) (Fig. 1d and Supplementary Table 1). In order to identify disease-related gene expression changes, we performed bulk RNA sequencing for four twin lines and four CTRL lines and compared group expressions to identify differentially expressed genes (DEGs). One of the twin pairs (pair 4) was excluded from RNA sequence due to poor sample quality. The success rate for differentiation was statistically similar for ST iMGL lines (67%, n = 18 attempts, χ2 test), HT iMGL lines (84%, n = 19) and CTRL iMGL lines (78%, n = 18) (Supplementary Fig. 2d).

We first looked at the expression of common homeostatic microglial markers as their downregulation has been previously implicated in SCZ [21]. None of analyzed markers showed within-pair differences, but the twins differed from CTRLs. AIF1 (Iba1) was significantly upregulated in both ST and HT iMGLs compared to CTRLs by nominal p value (ST p = 1.2 × 10−9, HT p = 0.032) and ST also by Bonferroni corrected p value (adj.p = 1.3 × 10−6) (Fig. 1e). Also PTPRC (CD45) was upregulated in ST twins compared to CTRL iMGL (p = 0.0012, adj.p = 0.0081), while TREM2 was downregulated in STs (p = 0.003) and TMEM119 downregulated in HTs (p = 0.030) compared to CTRL. Other analyzed microglia-specific markers showed no significant group difference, e.g., P2RY12, CX3CR1, ITGAM, and PROS1 (Supplementary Fig. 2c).

Twins with SCZ had aberrant expression of inflammatory genes and reduced IL6 response to IL1β

HLA-DR is one of the commonly used markers for microglial activation in postmortem studies [6, 22, 23]. Expression of HLA-DRA, as well as many other HLA class II genes, was upregulated in our ST iMGLs vs. CTRL iMGLs (HLA-DRA p = 5.2 × 10−5, adj.p = 0.0049) (Fig. 2a and Supplementary Fig. 3). The expression of pro-inflammatory cytokine IL1β was upregulated in ST vs. CTRL iMGLs (p = 0.021). On the other hand, TSPO, a controversial marker for inflammation used in PET imaging studies showed no significant alterations [24].Fig. 2 Inflammation, cytokine release and phagocytosis in iMGLs.

a Gene expression of inflammatory related HLA-DRA, TSPO and IL1β based on RNA sequencing. b Representative image after 4-h migration assay. Cells were masked with magenta for analysis. Scale bar 800 µm. c The number of migrated cells normalized to unstimulated condition for each group. Performed Kruskal–Wallis test (H(2) = 2.371, p = 0.3305; H(2) = 0.7829, p = 0.6927). d Release of IL6 (CTRL: χ2(3) = 10.33, p = 0.0030; ST: χ2(3) = 1.114, p = 0.8307; HT: χ2(3) = 5.864, p = 0.1132), IL8 (CTRL: χ2(3) = 8.400, p = 0.0190; ST: χ2(3) = 7.500, p = 0.0517; HT: χ2(3) = 7.800, p = 0.0443) and MCP1 (CTRL: χ2(3) = 5.100, p = 0.1897; ST: χ2(3) = 11.10, p = 0.0009; HT: χ2(3) = 9.72, p = 0.0120) cytokines after 24 h treatment with either 20 ng/ml IL1β, 20 ng/ml TNFα or 20 ng/ml IFNγ. Friedman test and Mann–Whitney test. e Gene expression of TLR2 and TLR4. f Representative image from phagocytosis after 6 h (Scale bar 100 µm) and (g) phagocytosis of pHrodo-zymosan bioparticles. h Phagocytosis between the groups after 6 h (H(2) = 0.7800, p = 0.7027). Kruskal–Wallis test. n = 4–5 cell lines.

Microglia are extremely motile and survey their environment for injuries and pathogens. In response to ATP and ADP, molecules secreted during neuronal damage, iMGLs showed more than five-fold increased migration (Fig. 2b, c). ST and HT iMGLs responded normally to both ATP and ADP, as the number of migrated iMGL cells did not differ between the groups (Kruskal–Wallis test). Next, we checked whether ST, HT and CTRL iMGLs respond differently to pro-inflammatory cytokines (IL1β, TNFα and IFNγ) measured as induced release of cytokines IL6, interleukin 8 (IL8) and TNFα and chemokine monocyte chemoattractant protein-1 (MCP1) 24 h after exposure. In unstimulated conditions, release of IL6 and TNFα was undetectable. As expected, CTRL iMGLs significantly increased the release of IL6 (p = 0.030) and IL8 (p = 0.019) after all the cytokine treatments. However, ST iMGLs significantly increased only MCP1 release (p = 0.0009, Friedman test). Between ST and CTRL, ST iMGLs had significantly reduced IL6 response to IL1β treatment (U = 0, p = 0.0286, Mann–Whitney test). These data indicate that ST iMGLs are less responsive to central cell-to-cell pro-inflammatory signals.

Recognition of pathogens is the first step of innate immune activation and thus precedes pro-inflammatory cytokine release. Toll-like receptors (TLRs) detect various viral, bacterial and fungal structures. Interestingly, we observed that TLR2 expression was significantly downregulated in ST iMGLs compared to CTRL iMGLs (p = 0.003), while TLR4 receptor showed no difference (Fig. 2e). To find out whether the decreased TLR2 expression of ST iMGLs is reflected as an altered ability to detect pathogens and phagocytose them, we incubated iMGLs with pHrodo-labeled zymosan bioparticles (Fig. 2f and Supplementary Fig. 4), which are recognized through TLR2, TLR6 and non-TLR receptor CLEC7A [25, 26]. A 6-h live imaging ST iMGL showed a slightly reduced phagocytosis of zymosan particles, but the reduction was not statistically significant (p = 0.70 Mann–Whitney test) (Fig. 2g, h).

SCZ iMGLs did not significantly alter neuronal activity in NGN2-neuron co-culture with iMGLs

In addition to neuroinflammation regulation, promotion of neurogenesis and synaptogenesis by neurotrophic factor secretion is another important function of microglia [27]. Especially brain-derived neurotrophic factor (BDNF) released by microglia enhances learning-related synapse formation [28]. BNDF is also one of the most considered biomarkers for SCZ, which has been found to be reduced in plasma samples in SCZ [29]. Interestingly, BDNF was significantly less expressed in both ST and HT iMGLs compared to CTRL iMGLs (p = 0.005 and p = 0.008, respectively) (Fig. 3a). iMGLs expressed also glial cell line-derived neurotrophic factor (GDNF), which has been reported to show de novo expression in microglia/macrophages upon neuroinflammation or injury [30], but its expression was similar in all three groups (Fig. 3a). Another neurotrophic factor that showed altered expression in ST iMGLs was mesencephalic astrocyte-derived neurotrophic factor (MANF), which in turn was upregulated in ST iMGLs vs. CTRL (p = 0.006, adj.p = 0.008). MANF has been reported to induce anti-inflammatory microglia polarization after endoplasmic reticulum-associated stress [31]. Microglia express different neurotransmitter receptors for communicating with neurons and glia [32–34]. We found that especially N-methyl-D-aspartate (NMDA)-receptor gene GRIN2D was highly expressed in iMGLs and showed downregulation in HT vs. CTRL (p = 0.015) (Fig. 3b).Fig. 3 Expression of neurotrophic factors and neural activity in co-culture model.

a Neurotrophic factor BDNF, GDNF and MANF and (b) neurotransmitter receptor GRIN2D, GRIK2 and GABRA2 gene expression. c Timeline for co-culture design and MEA recording. d Representative images from CTRL iMGL co-cultures at 30 and 60 days in vitro (DIV) with stainings for NGN2-neurons (MAP2, red), rat astrocytes (GLT1, magenta), iMGLs (ABI3, green), and nuclei (DAPI). e Representative raster plots from weekly CTRL iMGL co-culture MEA recordings. Spikes detected on individual electrodes marked with black lines, bursts with blue lines and network bursts with purple boxes. f MEA recording results as Number of spikes (95% CI of diff. = −27,769 to −3067, adj.p = 0.0212; 95% CI of diff. = −11,671 to −1434, adj.p = 0.0104; 95% CI of diff. = −8259 to −331.2, adj.p = 0.0366; 95% CI of diff. = −19,980 to −4147, adj.p = 0.0113), Weighted mean firing rate (95% CI of diff. = −2.821 to −0.4223, adj.p = 0.0152; 95% CI of diff. = −1.418 to −0.07197, adj.p = 0.0288; 95% CI of diff. = −2.117 to −0.3807, adj.p = 0.0139), Network IBI coefficient of variation (95% CI of diff. = −1.499 to −0.1199, adj.p = 0.0222; 95% CI of diff. = −1.181 to −0.4205, adj.p = 0.0060), and Synchrony index (95% CI of diff. = −0.6299 to −0.09522, adj.p = 0.0125; 95% CI of diff. = −0.6945 to −0.09386, adj.p = 0.0147) from co-culture with and without iMGLs. n = 5–7 wells for no iMGL and n = 6–10 wells from two CTRL iMGL lines. g MEA recording results as Number of spikes, Weighted mean firing rate, ISI coefficient of variation, Number of bursts, Burst duration (95% CI of diff. = −0.1197 to −0.007484, adj.p = 0.0368; 95% CI of diff. = −0.2053 to −0.05687, adj.p = 0.0165), Mean ISI within burst (95% CI of diff. = 0.0004615 to 0.01288, adj.p = 0.0436; 95% CI of diff. = 0.002695 to 0.01507, adj.p = 0.0248; 95% CI of diff. = 0.005213 to 0.007635, adj.p = 0.0019), Network IBI coefficient of variation (95% CI of diff. = −1.574 to −0.3703, adj.p = 0.0197; 95% CI of diff. = −1.173 to −0.1141, adj.p = 0.0331), and Synchrony index (95% CI of diff. = −0.3168 to −0.1937, adj.p = 0.0030; 95% CI of diff. = −0.6867 to −0.03380, adj.p = 0.0414) from ST, HT and CTRL iMGL co-cultures. n = 3 lines per group. Dunnett’s (timepoints compared to week 4 timepoint) or Tukey’s (comparison between with/without iMGL groups) multiple comparisons tests were used for significance. CTRL healthy individuals, ST affected twin, HT healthy twin.

Other neurotransmitter genes, such as kainate receptor GRIK2 and GABA-receptor GABRA2 were expressed only in low level, but were significantly downregulated in ST and HT compared to CTRL iMGLs (ST GRIK2 p = 0.0012; ST GABRA2 p = 0.0035, and HT GABRA2 p = 0.0045). Even though no microglial complement pathway genes (C1Q and C3) were expressed differently in ST or HT iMGLs (Supplementary Fig. 5), the reduction in neurotrophic factors and neurotransmitter expression suggests reduced potential for synaptic remodeling in microglia from patients with SCZ.

In order to investigate if the reduction in neurotrophic factor expressions in iMGLs from patients with SCZ leads to altered neuronal activity, we designed a tri-culture system with doxycycline-inducible Neurogenin 2 (NGN2)-expressing hiPSC-cortical neurons, rat astrocytes and iMGLs (Fig. 3c). Astrocyte, neuron, and microglial survival were verified by stainings with cell-type specific markers in 30 and 60 days old co-cultures (Fig. 3d and Supplementary Fig. 6). To follow functional maturation of the neurons in co-cultures, we used multi-electrode array (MEA) to detect neural activity and synchronicity. We were able to reliably detect network-level activity after 4 weeks in co-culture and follow it until 8 weeks (Fig. 3e and Supplementary Fig. 7). First, we tested how adding iMGLs changes neural firing by comparing co-cultures without iMGLs with two CTRL line iMGL co-cultures. Including iMGLs into co-culture system significantly reduced neural activity at 6- and 7-week time points (reduced number of spikes p = 0.021 and p = 0.01, lower weighted mean firing rate p = 0.015 and p = 0.029, Tukey’s multiple comparisons test) and the activity significantly increased by time in co-cultures without microglia (number of spikes 4 vs. 6 weeks p = 0.011, and mean firing rate 4 vs. 6 p = 0.01; Dunnett’s multiple comparisons test; Fig. 3f). On the other hand, Network IBI (inter-network burst interval) coefficient of variation for network burst rhythmicity and Synchrony index for spiking synchronicity were lower in iMGL containing co-cultures than without iMGLs (Network IBI coefficient of variation 4 weeks p = 0.022) and these measures increased over time until no differences were detectable between the co-cultures at later time points (Network IBI coefficient of variation 4 vs. 8 weeks p = 0.006, Synchrony index 4 vs. 6 weeks p = 0.013, 4 vs. 8 weeks p = 0.015). Additional data from burst and network burst metrics are collected in Supplementary Fig. 8. Thus, NGN2 neurons were firing less with iMGL co-cultures and it took longer for them to establish mature network-level activity.

Next, we compared the co-cultures with three female CTRL, ST or HT iMGL lines (Fig. 3g and Supplementary Fig. 9). Overall, there were no differences in neural spiking activity (number of spikes, weighted mean firing rate and ISI (inter-spike interval) coefficient of variation) between neurons co-cultured with CTRL, HT, and ST-derived iMGLs. The number of bursts was not altered either, but the burst duration was significantly increased in HT vs. CTRL iMGL co-cultures at 4-week time point (p = 0.037), and between 4 and 8 weeks in CTRL iMGLs (p = 0.017), but not in ST or HT iMGL co-cultures. Mean ISI within bursts significantly decreased over time in CTRL iMGLs indicating increased spiking within bursts (in CTRLs 4 vs. 5 weeks p = 0.047, 4 vs. 6 weeks p = 0.025, 4 vs. 8 weeks p = 0.002). The only significant difference between ST iMGL co-cultures compared with CTRL or HT co-cultures was an increase between ST and CTRL iMGLs in Network IBI coefficient of variation at the 4-week time point (p = 0.033). This indicates greater irregularity in neuronal network bursting in ST iMGL containing cultures. No significant changes were detected in ST iMGL co-culture neural network activity compared to the 4-week time point, but bursting in CTRL and HT iMGL co-cultures slightly improved over time. ST iMGL cultures gave more mature firing earlier than CTRL and HT co-cultures, but we did not see changes in ST iMGLs over time. However, before 4 weeks of age only a small number of electrodes per well showed activity, hence it was not reliable to use earlier time point. We conclude that even though the electrophysiological properties of NGN neurons were slightly differentially affected by ST, HT and control iMGLs, the iMGL co-culture system did not produce clear evidence for the impact of ST iMGLs on neuronal activity.

Global downregulation of genes was associated with increased risk to develop SCZ and upregulation of MHC region to clinical manifestation of SCZ

We further examined comprehensively the DEGs between the study groups (Fig. 4a). While the ST twins differed significantly from the HT twins only by 2 DEGs (adj.p < 0.05, abs log2FC > 1), we found more expression changes related to clinical illness (ST vs. CTRL, 456 DEGs) than increased risk to develop SCZ (HT vs. CTRL, 123 DEGs) (Supplementary Data file 1–3). Most of the SCZ-related gene expression changes were reductions, as 77.4% of the DEGs in ST vs. CTRL and 99.2% in HT vs. CTRL were downregulated. These comparisons overlapped by 66 DEGs, which is 53.7% of altered expression changes in the HT vs. CTRL comparison and 14.5% in the ST vs. CTRL comparison (Fig. 4b).Fig. 4 iMGL expression profile and pathway analysis.

a Overview of differentially expressed genes (DEGs) in different comparisons. b Venn diagram of shared DEGs between HT vs. CTRL and ST vs. CTRL. Ingenuity Pathway Analysis (IPA) canonical pathways (c) from ST vs. CTRL and (d) HT vs. CTRL comparisons. Cutt-offs: Fold change > abs 2, adjusted p < 0.05. e Downregulated and (f) upregulated Gene Ontology (GO) Molecular function terms from ST vs. CTRL comparison and (g) downregulated terms from HT vs. CTRL comparison. CTRL healthy individuals, ST affected twin, HT healthy twin. RNAseq n = 4 lines in each group.

Next, we used Ingenuity Pathway Analysis (IPA) to identify canonical pathways related to DEGs in ST or HT vs. CTRL comparisons in iMGLs (adj.p < 0.05 and abs log2FC > 1 threshold for DEGs). Both twin comparisons to CTRL group shared the first four pathways, which together with Wound Healing Signaling Pathway and Pulmonary Fibrosis Idiopathic Signaling Pathway contained Hepatic Fibrosis/Hepatic Stellate Cell Activation (−log10(p value) = 11.5 in ST vs. CTRL and 10.9 in HT vs. CTRL) and GP6 Signaling Pathway (−log10(p value) = 5.1 in ST vs. CTRL and 4.5 in HT vs. CTRL). These pathways include genes encoding extracellular matrix molecules and have been identified in previous studies with the same cohort to be involved in hiPSC-neuron and hiPSC-astrocyte dysregulation in ST [35, 36] (Fig. 4c, d and Supplementary Data files 4 and 5).

In order to study down- and upregulated DEGs separately, we used additionally Gene Ontology (GO) term analysis (Supplementary Data file 6–8). Downregulated GO Molecular function terms were similar between ST vs. CTRL and HT vs. CTRL (Fig. 4e, g). The most significant functions were Extracellular matrix structural constituent (−log10(p value) = 16.4 in ST vs. CTRL and 11.8 in HT vs. CTRL), Extracellular matrix structural constituent conferring tensile strength(−log10(p value) = 11.1 in ST vs. CTRL and 7.3 in HT vs. CTRL), and Heparin binding (−log10(p value) = 6.3 in ST vs. CTRL and 4.7 in HT vs. CTRL) terms. These pathways shared several collagen genes.

In turn, the upregulated GO terms in STs compared to CTRLs were related to Protein heterodimerization (−log10(p value) = 11.0) and MHC class II receptor activities (−log10(p value) = 2.3) (Fig. 4f). The first functional term contains several histone modification genes of which Clustered Histone genes H3C12, H2BC17, H2AC13, H3C10, and H3C11 (5/18 DEGs) belong to a small cluster of histone genes in chromosome 6p22.1, which is in close proximity of MHC region (Supplementary Data file 7) [37]. Also nine out of 18 DEGs belonged to a large histone cluster in 6p22.2. MHC class II receptor activity term consists of HLA-genes (HLA-DQA2 and HLA-DQB2 genes in Supplementary Fig. 3). Thus, clinical manifestation of SCZ is associated with activation of chromosome 6 MHC region in iMGLs.

Heterogeneous response to different drug treatments in twins with SCZ

As STs showed specific dysregulations to several SCZ-associated genes, we tested if these transcriptomic changes can be rescued either with clozapine, an efficient atypical antipsychotic drug, minocycline, a tetracycline antibiotic proposed also as treatment of negative symptoms in SCZ due to its anti-inflammatory properties, and sulforaphane, an organosulfur isothiocyanate antioxidant with histone deacetylase inhibitory properties proposed for treatment of cognitive functions for patients with SCZ. We selected the drug concentration range from previously used cell culture studies with primary murine microglia or BV2 cell line microglia [12, 17, 38], and tested the suitable concentration by viability assay. Clozapine and sulforaphane had dose-dependent decreased effect on cell viability after 24 h, while minocycline showed no clear toxicity up to 100 µM concentration (Fig. 5a).Fig. 5 iMGL responses to different drug treatments.

a Viability of iMGLs after 24-h treatment with clozapine (W = −21.00, p = 0.0313 all), minocycline and sulforaphane (W = −21.00, p = 0.0313). Tested with four independent experiments with two control, two HT and two ST lines (n = 6 lines) (Wilcoxon test). b NFκB pathway downstream gene FOS. Heatmaps of CTRL, ST and HT line gene expression changes after (c) 10 µM clozapine (d) 10 µM minocycline and (e) 5 µM sulforaphane treatments. No data from ST5 patient after clozapine and sulforaphane. f Gene expression differences after drug treatments in BDNF, HLA-DRA, TLR2 and IL1β. RNAseq n = 3–4 lines in each group. CTRL healthy individuals, ST affected twin, HT healthy twin.

We tested the drug effect on phagocytosis, as minocycline has been previously shown to reduce phagocytosis of synaptic material dose-dependently in monocyte-derived microglia [12]. Phagocytosis was significantly increased after 24-h treatment with 10 µM sulforaphane, but no significant changes were discovered after clozapine or minocycline treatment (Supplementary Fig. 10a, c). We repeated the experiment with iMφs, but again only sulforaphane significantly increased phagocytosis of zymosan, and the highest used concentration of clozapine and sulforaphane were toxic and caused significant reduction in phagocytosis (Supplementary Fig. 10b, d). As we could not detect any response in phagocytosis of zymosan after minocycline treatment, this drug might inhibit only complement system mediated synapse phagocytosis as previously reported [12].

We continued using drug concentrations which did not affect viability (clozapine 10 µM, minocycline 10 µM and sulforaphane 5 µM), and performed RNA sequencing for drug treatments as well. All of the three drugs have been suggested to suppress NF-κB pro-inflammatory pathway activation as one beneficial mechanism. NF-κB downstream transcription factor FOS was significantly downregulated in CTRL iMGLs after 24-h minocycline and sulforaphane treatments, but not after clozapine treatment (Fig. 5b). However, the same downregulation was not seen in ST or HT twins untreated vs. treated. None of the drugs had any significant effect on IL8 and MCP-1 release (Supplementary Fig. 10e–g).

As clozapine inhibits NF-κB activation by inhibiting Akt pathway and sulforaphane promotes anti-inflammatory activation and microglia process elongation through Akt activation [17, 39], we performed western blot for phosphorylated NF-κB and Akt. Clozapine reduced significantly Akt phosphorylation in HT, whereas the response of HTs to NF-κB phosphorylation and of STs to both Akt and NF-κB varied (Supplementary Fig. 11a, b). Sulforaphane especially induces NRF2 pathway, and this pathway’s downstream targets GCLM and HMOX1 were significantly upregulated on transcriptomic level in CTRL and HT untreated vs. sulforaphane as expected, but not in ST (Supplementary Fig. 11c).

ST microglia appeared less-responsive to drug treatments HT and CTRL iMGLs, so next we compared the significant DEGs between untreated and drug-treated in CTRL, ST or HT groups (p value < 0.05, abs log2FC > 1). Interestingly, especially ST iMGLs had heterogeneous response to drug treatments (Fig. 5c clozapine, d minocycline, e sulforaphane, Supplementary Data file 12–17). While iMGLs of all CTRL lines responded similarly to drug treatments, iMGLs of ST1 patient had stronger response to clozapine, iMGLs of ST3 and ST5 patients a stronger response to minocycline and iMGLs of ST3 patient a stronger response to sulforaphane than iMGLs of other ST patients. It is to be note that we had data from ST5 iMGL response only after minocycline treatment. The iMGLs of different HT lines showed consistent responses to both clozapine and minocycline treatments, with exception of HT5 iMGLs, which responded differently after clozapine and minocycline treatments.

Sulforaphane has been previously shown to upregulate BDNF in BV2 microglia cell line [16]. While we did not detect upregulation of BDNF after sulforaphane treatment in iMGLs of any individual, we noticed a significant upregulation of BDNF expression after clozapine and minocycline treatments in ST iMGLs (Fig. 5f). However, while minocycline has been shown to reduce expression of MHC class II genes, TLR2 and IL1β in rodent microglia [13, 14, 40], minocycline treatment did not results in such gene expression changes in our iMGL cells of any individual. Instead, HLA-DRA expression was downregulated in CTRL but not ST or HT iMGL group after sulforaphane treatment. Similarly, IL1β expression was reduced only in CTRL iMGL group after clozapine and sulforaphane. None of the treatments resulted in altered TLR2 expression in any iMGL group. Altogether, iMGLs of monozygotic twins from pairs discordant for SCZ appear to be less responsive than iMGLs of healthy controls to drug treatments that have been previously shown to affect microglia and be relevant for treating SCZ.

ST twin iMGLs did not activate differently after LPS-induced inflammation

Lipopolysaccharide (LPS) stimulation is the most common way to induce microglial inflammation. LPS activation occurs especially through TLR4-mediated NF-κB pathway activation. To see whether ST or HT iMGLs are more sensitive for LPS-induced activation, we treated iMGLs for 24 h with LPS and measured the cytokine release and phagocytosis of zymosan bioparticles. However, no differences were observed in IL6, IL8 and MCP1 secretion after LPS treatment between the groups (Fig. 6a). Similarly, LPS had no significant effect on phagocytosis in any of the groups (p = 0.49, CTRL; 0.54, ST; 0.63, HT; Friedman test) (Fig. 6b). Clozapine, minocycline and sulforaphane have all been reported to suppress LPS-induced activations of mouse primary microglia or BV2 microglia [17, 18, 38, 40, 41]. However, none of the drugs added 1 h prior to LPS was able to reduce IL6, IL8, MCP1 or TNFα release (Fig. 6c and Supplementary Fig. 12).Fig. 6 Drug treatment protection from LPS-induced inflammation in iMGLs.

a IL6 (H(2) = 0.9800, p = 0.6500), IL8 (H(2) = 1.8600, p = 0.4163) and MCP1 (H(2) = 1.220, p = 0.5824) secretion after 24-h 100 ng/ml LPS treatment between the groups. Kruskal–Wallis test. b LPS effect on pHrodo-zymosan phagocytosis after 24-h LPS treatment and 6 h after adding pHrodo bioparticles (CTRL: H(4) = 3.397, p = 0.4937; ST: H(4) = 3.094, p = 0.5422; HT: H(4) = 2.592, p = 0.6282). Kruskal–Wallis test. c IL6 (χ2(4) = 5.400, p = 0.1514), IL8 (χ2(4) = 6.360, p = 0.0933), MCP1 (χ2(4) = 3.480, p = 0.3720) and TNFα (χ2(4) = 3.735, p = 0.3141) secretion in CTRL iMGL cultures after 30 min pre-treatment with 10 µM clozapine, 10 µM minocycline or 5 µM sulforaphane and 24-h 100 ng/ml LPS treatment. Friedman test, n = 5 lines.

Discussion

Microglia are brain residential immune cells which have arisen from the yolk sac and migrated to brain during development. Microglia are thus the first developed glial cell type in the brain. hiPSC differentiation allows us to generate a pure population of human microglia cell cultures [20, 42]. Human iMGLs are distinct from hematopoietic stem cells and monocytes and cluster closely with cultured human fetal and adult microglia by their RNA expression profile, as previously described [20]. We showed in this study that also iMGL gene expression was different than in hiPSC-derived macrophages. All our hiPSC-lines included in the experiment were able to differentiate into iMGLs and by their morphology and marker expression resembled resting microglia. Even though pair 4 was excluded from RNA sequencing, we were able to include all five monozygotic twins discordant for SCZ to the other experiments after preparing additional iMGL batches and careful quality controls.

hiPSC-microglia-like cells from patients with SCZ were recently shown to have increased synaptic pruning activity in neuronal co-cultures and enhanced inflammasome activity [11]. In this study, we showed that microglia from the patients with SCZ have a strong genetic component contributing to dysregulation of homeostatic and inflammatory gene expression. Since the differences between the affected twins and healthy co-twins were small, we focused on differences between twins and CTRLs. So far, human microglia are mostly studied from postmortem tissue by their morphology, cell density, and the expression of different cellular markers in particular brain areas [22, 23]. Increase of microglial inflammation markers in postmortem SCZ brains is commonly detected when studying microglia density in different brain regions, although there are contradictive results as well [6, 7, 21, 23]. HLA-DRA cell density has been found to be increased in several studies, but gene expression studies have shown no difference in patients with SCZ [21, 23, 43]. Similar variation has been seen in cytokine and chemokine expression studies [23]. However, analyses of postmortem samples represent only the late stage changes, and are affected by antipsychotic drugs while iMGLs recapitulate microglia phenotype that is only genotype-dependent.

Chronic hyperactivation leading to microglia priming has been proposed to be characterized by higher expression of inflammatory markers, higher sensitivity for activation, and exaggerated inflammatory response, when compared to unprimed microglia [44]. Although iMGLs from patients with SCZ had increased transcriptomic expression of several inflammatory markers, they showed no hyperactivation in a sense of increased cytokine production or increased migration or phagocytosis. Moreover, LPS-induced inflammation had no additional effect on iMGL proinflammatory cytokine release or phagocytosis. The latest studies have pointed out that only a subgroup of patients with SCZ show signs of increased inflammation [6]. Thus, it is possible that the patient iMGLs would not develop high inflammatory responses as hypothesized earlier.

The MHC locus is one of the earliest reported sites on the human genome associated with SCZ and the strongest association with SCZ in GWAS [9, 45]. Microglia are the main MHC class II -expressing antigen-presenting cell in the brain, which can attract antigen-specific CD4+ T lymphocytes to sites of inflammation [46, 47]. Our data suggest that upregulation of MHC class II genes is associated with clinical manifestation of SCZ. In fact, postmortem studies have found increased lymphocyte infiltration in a subset of patients with SCZ [48, 49]. Upregulation of MHC class II genes could be an early pathophysiological change that leads to SCZ manifestation later in life. According to a new hypothesis, infiltrated regulatory T lymphocytes activate astrocytes, which in turn by increasing TGFβ secretion force microglia to sustain in non-inflammatory state and promote microglial phagocytosis and pruning in patients with SCZ [50, 51]. Further studies with co-cultures, cerebral organoids and xenotransplantation of microglia [42] are needed to assess the interaction between different cell types and their effect on microglia functions.

Downregulation of microglia transcriptome in SCZ have been shown by studies integrating RNA-sequence and genetic data [52]. Downregulation of extracellular matrix constitution genes was detected from both twins compared to healthy individuals. Alterations in hepatic fibrosis and GP6 signaling pathways in microglia from patients with SCZ are shared with our previous studies in hiPSC-cortical neurons and hiPSC-astrocytes of the same individuals [35, 36] indicating universal dysregulation of these pathways. The hepatic fibrosis pathways consists of mostly different collagen genes, which are not liver-specific despite the name of the pathway. Extracellular matrix molecules have multiple roles during development to support neuronal migration and synapse formation [53]. Extracellular matrix components may induce or suppress microglial activation, their proliferation, migration and production of inflammatory cytokines as their ability to regulate synaptogenesis and neuronal transmission [53–55].

Neurogenesis is strongly influenced by microglia in the production, maturation, and integration of new neurons into circuitry by inducing neurotrophic factors and pruning weak synapses [27]. In addition, microglia-derived pro-inflammatory molecules have been shown to inhibit neurogenesis [56, 57]. We observed reduced expression of neurotrophic factors and transmitter receptors in iMGLs of affected twin pairs indicating microglia-regulated changes in modulation of neural maturation and neural transmission in patients with SCZ, while the effect on neuronal activity in co-culture system showed only subtle changes in the presence of SCZ iMGLs.

In summary, these data suggest that the increased risk to develop SCZ is associated with cell-autonomous downregulation of extracellular matrix and growth factor binding related transcriptional changes, and upregulation of inflammatory genes with clinical illness in microglia, without increased microglial pro-inflammatory activation. Microglia responses to clozapine, minocycline and sulforaphane differed from each other especially for individual patients in the group of SCZ. These findings demonstrate that drug candidates for treatment of SCZ and possibly for other mental disorders need to be tested in patient-derived models and not only in material derived from animals or healthy individuals.

Limitation of the study

Microglia adapt rapidly to environment changes and ex vivo microglia change their expression profile compared to in vivo [58]. Thus, cultured microglia may not capture all gene expression changes, but human microglia states are conserved across different in vivo and hiPSC-microglia experimental models although some key homeostatic genes have lower expression [59]. Also, microglia in vitro tend to be more activated and secrete more cytokines than microglia in vivo, which could mask some differences in microglial responses to inflammatory stimuli. The most common reason for a sample exclusion was spontaneous activation of microglia during differentiation, leading to cell apoptosis. This was more batch-specific phenomenon than related to disease status. As some of the observed differences between the groups were high but not significant, availability of additional twin pairs discordant for SCZ could have increased the statistical power of our findings. Additional studies with large patient cohorts are needed to further validate our findings.

Supplementary information

Supplementary Information

Supplementary Data Files

Supplementary information

The online version contains supplementary material available at 10.1038/s41380-024-02529-1.

Acknowledgements

We thank technicians Anne Nyberg and Agnes Viherä for their help in cell culture.

Author contributions

Jari Tiihonen and Jari Koistinaho conceived the study. Marja Koskuvi planned the experiments, differentiated microglia, prepared RNA and ICC samples, performed live cell experiments (phagocytosis, migration, MTT), run qRT-PCR, and assisted with CBA. Elina Pörsti assisted in microglia differentiation, performed ICC stainings, WB, and imaging, processed RNA sequencing data analysis with IPA and GO term analyses, and run CBA. Ying-Chieh Wu established hiPSC-macrophage protocol and differentiated hiPSC-macrophages, assisted with CBA and WB. Kalevi Trontti and Iiris Hovatta performed RNA sequencing samples, supervised sequencing analyses and contributed to the interpretation of the results. Amanda McQuade and Mathew Blurton-Jones established the iMGL protocol and guided in iMGL differentiation. Tyrone D. Cannon, Jouko Lönnqvist, Sebastian Therman, Jaana Suvisaari, and Jaakko Kaprio gathered the data on twin pairs. Ilkka Ojansuu and Olli Vaurio performed skin biopsies and rating of symptoms. Jari Tiihonen and Markku Lähteenvuo coordinated patient data collection and contributed to the interpretation of the results. Šárka Lehtonen supervised microglia differentiation. Taisia Rolova supervised differentiation of microglia and macrophages, and experiments with phagocytosis, CBA and WB and contributed to the interpretation of the results. Tristen Hewitt, Noora Räsänen and Shringaa Kalyanaraman designed and performed co-culture studies. Marja Koskuvi wrote the first draft of the manuscript and prepared the figures and tables with the help from Jari Koistinaho, Jari Tiihonen, Elina Pörsti and Tristen Hewitt.

Funding

J Koistinaho has been supported by the Academy of Finland (grant 334525), Business Finland and Sigrid Juselius Foundation. J Kaprio has been supported by the Academy of Finland (grant 336823). Open Access funding provided by University of Helsinki (including Helsinki University Central Hospital).

Data availability

Supplementary Data files contain raw RNA seq comparisons, IPA pathway analyses, and GO terms. The RNA sequencing data will be made available in EGA (European Genome-phenome Archive) upon request to the corresponding author.

Competing interests

The authors declare no competing interests.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
==== Refs
References

1. Fond G Lançon C Korchia T Auquier P Boyer L The role of inflammation in the treatment of schizophrenia Front Psychiatry 2020 11 160 10.3389/fpsyt.2020.00160 32256401
Fond G, Lançon C, Korchia T, Auquier P, Boyer L. The role of inflammation in the treatment of schizophrenia. Front Psychiatry. 2020;11:160.32256401
2. Murphy CE Walker AK Weickert CS Neuroinflammation in schizophrenia: the role of nuclear factor kappa B Transl Psychiatry 2021 11 528 10.1038/s41398-021-01607-0 34650030
Murphy CE, Walker AK, Weickert CS. Neuroinflammation in schizophrenia: the role of nuclear factor kappa B. Transl Psychiatry. 2021;11:528.34650030
3. Wahbeh MH Avramopoulos D Gene-environment interactions in schizophrenia: a literature review Genes 2021 12 1850 10.3390/genes12121850 34946799
Wahbeh MH, Avramopoulos D. Gene-environment interactions in schizophrenia: a literature review. Genes. 2021;12:1850.34946799
4. Monji A Kato T Kanba S Cytokines and schizophrenia: microglia hypothesis of schizophrenia: cytokines and schizophrenia Psychiatry Clin Neurosci 2009 63 257 65 10.1111/j.1440-1819.2009.01945.x 19579286
Monji A, Kato T, Kanba S. Cytokines and schizophrenia: microglia hypothesis of schizophrenia: cytokines and schizophrenia. Psychiatry Clin Neurosci. 2009;63:257–65.19579286
5. Gober R Ardalan M Shiadeh SMJ Duque L Garamszegi SP Ascona M Microglia activation in postmortem brains with schizophrenia demonstrates distinct morphological changes between brain regions Brain Pathol 2022 32 e13003 10.1111/bpa.13003 34297453
Gober R, Ardalan M, Shiadeh SMJ, Duque L, Garamszegi SP, Ascona M, et al. Microglia activation in postmortem brains with schizophrenia demonstrates distinct morphological changes between brain regions. Brain Pathol. 2022;32:e13003.34297453
6. Fillman SG Cloonan N Catts VS Miller LC Wong J McCrossin T Increased inflammatory markers identified in the dorsolateral prefrontal cortex of individuals with schizophrenia Mol Psychiatry 2013 18 206 14 10.1038/mp.2012.110 22869038
Fillman SG, Cloonan N, Catts VS, Miller LC, Wong J, McCrossin T, et al. Increased inflammatory markers identified in the dorsolateral prefrontal cortex of individuals with schizophrenia. Mol Psychiatry. 2013;18:206–14.22869038
7. Steiner J Mawrin C Ziegeler A Bielau H Ullrich O Bernstein HG Distribution of HLA-DR-positive microglia in schizophrenia reflects impaired cerebral lateralization Acta Neuropathol 2006 112 305 16 10.1007/s00401-006-0090-8 16783554
Steiner J, Mawrin C, Ziegeler A, Bielau H, Ullrich O, Bernstein HG, et al. Distribution of HLA-DR-positive microglia in schizophrenia reflects impaired cerebral lateralization. Acta Neuropathol. 2006;112:305–16.16783554
8. Goldsmith DR Rapaport MH Miller BJ A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression Mol Psychiatry 2016 21 1696 709 10.1038/mp.2016.3 26903267
Goldsmith DR, Rapaport MH, Miller BJ. A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression. Mol Psychiatry. 2016;21:1696–709.26903267
9. Schizophrenia Working Group of the Psychiatric Genomics Consortium. Biological insights from 108 schizophrenia-associated genetic loci Nature 2014 511 421 7 10.1038/nature13595 25056061
Schizophrenia Working Group of the Psychiatric Genomics Consortium. Biological insights from 108 schizophrenia-associated genetic loci. Nature. 2014;511:421–7.25056061
10. Mokhtari R Lachman HM The major histocompatibility complex (MHC) in schizophrenia: a review J Clin Cell Immunol 2016 07 479 10.4172/2155-9899.1000479
Mokhtari R, Lachman HM. The major histocompatibility complex (MHC) in schizophrenia: a review. J Clin Cell Immunol. 2016;07:479.
11. Breitmeyer R Vogel S Heider J Hartmann SM Wüst R Keller AL Regulation of synaptic connectivity in schizophrenia spectrum by mutual neuron-microglia interaction Commun Biol 2023 6 472 10.1038/s42003-023-04852-9 37117634
Breitmeyer R, Vogel S, Heider J, Hartmann SM, Wüst R, Keller AL, et al. Regulation of synaptic connectivity in schizophrenia spectrum by mutual neuron-microglia interaction. Commun Biol. 2023;6:472.37117634
12. Sellgren CM Gracias J Watmuff B Biag JD Thanos JM Whittredge PB Increased synapse elimination by microglia in schizophrenia patient-derived models of synaptic pruning Nat Neurosci 2019 22 374 85 10.1038/s41593-018-0334-7 30718903
Sellgren CM, Gracias J, Watmuff B, Biag JD, Thanos JM, Whittredge PB, et al. Increased synapse elimination by microglia in schizophrenia patient-derived models of synaptic pruning. Nat Neurosci. 2019;22:374–85.30718903
13. Tikka T Fiebich BL Goldsteins G Keinänen R Koistinaho J Minocycline, a tetracycline derivative, is neuroprotective against excitotoxicity by inhibiting activation and proliferation of microglia J Neurosci 2001 21 2580 8 10.1523/JNEUROSCI.21-08-02580.2001 11306611
Tikka T, Fiebich BL, Goldsteins G, Keinänen R, Koistinaho J. Minocycline, a tetracycline derivative, is neuroprotective against excitotoxicity by inhibiting activation and proliferation of microglia. J Neurosci. 2001;21:2580–8.11306611
14. Yrjänheikki J Tikka T Keinänen R Goldsteins G Chan PH Koistinaho J A tetracycline derivative, minocycline, reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic window Proc Natl Acad Sci 1999 96 13496 500 10.1073/pnas.96.23.13496 10557349
Yrjänheikki J, Tikka T, Keinänen R, Goldsteins G, Chan PH, Koistinaho J. A tetracycline derivative, minocycline, reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic window. Proc Natl Acad Sci. 1999;96:13496–500.10557349
15. Zhang JC Yao W Dong C Yang C Ren Q Ma M Prophylactic effects of sulforaphane on depression-like behavior and dendritic changes in mice after inflammation J Nutr Biochem 2017 39 134 44 10.1016/j.jnutbio.2016.10.004 27833054
Zhang JC, Yao W, Dong C, Yang C, Ren Q, Ma M, et al. Prophylactic effects of sulforaphane on depression-like behavior and dendritic changes in mice after inflammation. J Nutr Biochem. 2017;39:134–44.27833054
16. Tang R Cao QQ Hu SW He LJ Du PF Chen G Sulforaphane activates anti-inflammatory microglia, modulating stress resilience associated with BDNF transcription Acta Pharm Sin 2022 43 829 39 10.1038/s41401-021-00727-z
Tang R, Cao QQ, Hu SW, He LJ, Du PF, Chen G, et al. Sulforaphane activates anti-inflammatory microglia, modulating stress resilience associated with BDNF transcription. Acta Pharm Sin. 2022;43:829–39.
17. Jeon S Kim SH Shin SY Lee YH Clozapine reduces Toll-like receptor 4/NF-κB-mediated inflammatory responses through inhibition of calcium/calmodulin-dependent Akt activation in microglia Prog Neuropsychopharmacol Biol Psychiatry 2018 81 477 87 10.1016/j.pnpbp.2017.04.012 28431901
Jeon S, Kim SH, Shin SY, Lee YH. Clozapine reduces Toll-like receptor 4/NF-κB-mediated inflammatory responses through inhibition of calcium/calmodulin-dependent Akt activation in microglia. Prog Neuropsychopharmacol Biol Psychiatry. 2018;81:477–87.28431901
18. Kobayashi K Imagama S Ohgomori T Hirano K Uchimura K Sakamoto K Minocycline selectively inhibits M1 polarization of microglia Cell Death Dis 2013 4 e525 10.1038/cddis.2013.54 23470532
Kobayashi K, Imagama S, Ohgomori T, Hirano K, Uchimura K, Sakamoto K, et al. Minocycline selectively inhibits M1 polarization of microglia. Cell Death Dis. 2013;4:e525.23470532
19. Tiihonen J Koskuvi M Storvik M Hyötyläinen I Gao Y Puttonen KA Sex-specific transcriptional and proteomic signatures in schizophrenia Nat Commun 2019 10 3933 10.1038/s41467-019-11797-3 31477693
Tiihonen J, Koskuvi M, Storvik M, Hyötyläinen I, Gao Y, Puttonen KA, et al. Sex-specific transcriptional and proteomic signatures in schizophrenia. Nat Commun. 2019;10:3933.31477693
20. McQuade A Coburn M Tu CH Hasselmann J Davtyan H Blurton-Jones M Development and validation of a simplified method to generate human microglia from pluripotent stem cells Mol Neurodegener 2018 13 67 10.1186/s13024-018-0297-x 30577865
McQuade A, Coburn M, Tu CH, Hasselmann J, Davtyan H, Blurton-Jones M. Development and validation of a simplified method to generate human microglia from pluripotent stem cells. Mol Neurodegener. 2018;13:67.30577865
21. Snijders GJLJ Zuiden W Sneeboer MAM Berdenis van Berlekom A Geest AT Schnieder T A loss of mature microglial markers without immune activation in schizophrenia Glia 2021 69 1251 67 10.1002/glia.23962 33410555
Snijders GJLJ, Zuiden W, Sneeboer MAM, Berdenis van Berlekom A, Geest AT, Schnieder T, et al. A loss of mature microglial markers without immune activation in schizophrenia. Glia. 2021;69:1251–67.33410555
22. Jurga AM Paleczna M Kuter KZ Overview of general and discriminating markers of differential microglia phenotypes Front Cell Neurosci 2020 14 198 10.3389/fncel.2020.00198 32848611
Jurga AM, Paleczna M, Kuter KZ. Overview of general and discriminating markers of differential microglia phenotypes. Front Cell Neurosci. 2020;14:198.32848611
23. Trépanier MO Hopperton KE Mizrahi R Mechawar N Bazinet RP Postmortem evidence of cerebral inflammation in schizophrenia: a systematic review Mol Psychiatry 2016 21 1009 26 10.1038/mp.2016.90 27271499
Trépanier MO, Hopperton KE, Mizrahi R, Mechawar N, Bazinet RP. Postmortem evidence of cerebral inflammation in schizophrenia: a systematic review. Mol Psychiatry. 2016;21:1009–26.27271499
24. Plavén-Sigray P Matheson GJ Coughlin JM Hafizi S Laurikainen H Ottoy J Meta-analysis of the glial marker TSPO in psychosis revisited: reconciling inconclusive findings of patient–control differences Biol Psychiatry 2021 89 e5 8 10.1016/j.biopsych.2020.05.028 32682565
Plavén-Sigray P, Matheson GJ, Coughlin JM, Hafizi S, Laurikainen H, Ottoy J, et al. Meta-analysis of the glial marker TSPO in psychosis revisited: reconciling inconclusive findings of patient–control differences. Biol Psychiatry. 2021;89:e5–8.32682565
25. Underhill DM Macrophage recognition of zymosan particles J Endotoxin Res 2003 9 176 80 10.1177/09680519030090030601 12831459
Underhill DM. Macrophage recognition of zymosan particles. J Endotoxin Res. 2003;9:176–80.12831459
26. Schorey J Lawrence C The pattern recognition receptor dectin-1: from fungi to mycobacteria Curr Drug Targets 2008 9 123 9 10.2174/138945008783502430 18288963
Schorey J, Lawrence C. The pattern recognition receptor dectin-1: from fungi to mycobacteria. Curr Drug Targets. 2008;9:123–9.18288963
27. Pérez-Rodríguez DR Blanco-Luquin I Mendioroz M The participation of microglia in neurogenesis: a review Brain Sci 2021 11 658 10.3390/brainsci11050658 34070012
Pérez-Rodríguez DR, Blanco-Luquin I, Mendioroz M. The participation of microglia in neurogenesis: a review. Brain Sci. 2021;11:658.34070012
28. Parkhurst CN Yang G Ninan I Savas JN Yates JR Lafaille JJ Microglia promote learning-dependent synapse formation through brain-derived neurotrophic factor Cell 2013 155 1596 609 10.1016/j.cell.2013.11.030 24360280
Parkhurst CN, Yang G, Ninan I, Savas JN, Yates JR, Lafaille JJ, et al. Microglia promote learning-dependent synapse formation through brain-derived neurotrophic factor. Cell 2013;155:1596–609.24360280
29. Nieto RR Carrasco A Corral S Castillo R Gaspar PA Bustamante ML BDNF as a biomarker of cognition in schizophrenia/psychosis: an updated review Front Psychiatry 2021 12 662407 10.3389/fpsyt.2021.662407 34220575
Nieto RR, Carrasco A, Corral S, Castillo R, Gaspar PA, Bustamante ML, et al. BDNF as a biomarker of cognition in schizophrenia/psychosis: an updated review. Front Psychiatry. 2021;12:662407.34220575
30. Duarte Azevedo M Sander S Tenenbaum L GDNF, a neuron-derived factor upregulated in glial cells during disease J Clin Med 2020 9 456 10.3390/jcm9020456 32046031
Duarte Azevedo M, Sander S, Tenenbaum L. GDNF, a neuron-derived factor upregulated in glial cells during disease. J Clin Med. 2020;9:456.32046031
31. Yang F Li WB Qu YW Gao JX Tang YS Wang DJ Bone marrow mesenchymal stem cells induce M2 microglia polarization through PDGF-AA/MANF signaling World J Stem Cells 2020 12 633 58 10.4252/wjsc.v12.i7.633 32843919
Yang F, Li WB, Qu YW, Gao JX, Tang YS, Wang DJ, et al. Bone marrow mesenchymal stem cells induce M2 microglia polarization through PDGF-AA/MANF signaling. World J Stem Cells. 2020;12:633–58.32843919
32. Liu H Leak RK Hu X Neurotransmitter receptors on microglia Stroke Vasc Neurol 2016 1 52 8 10.1136/svn-2016-000012 28959464
Liu H, Leak RK, Hu X. Neurotransmitter receptors on microglia. Stroke Vasc Neurol. 2016;1:52–8.28959464
33. Domercq M Vázquez-Villoldo N Matute C Neurotransmitter signaling in the pathophysiology of microglia Front Cell Neurosci 2013 7 49 23626522
Domercq M, Vázquez-Villoldo N, Matute C. Neurotransmitter signaling in the pathophysiology of microglia. Front Cell Neurosci. 2013;7:49.23626522
34. Logiacco F Xia P Georgiev SV Franconi C Chang YJ Ugursu B Microglia sense neuronal activity via GABA in the early postnatal hippocampus Cell Rep 2021 37 110128 10.1016/j.celrep.2021.110128 34965412
Logiacco F, Xia P, Georgiev SV, Franconi C, Chang YJ, Ugursu B, et al. Microglia sense neuronal activity via GABA in the early postnatal hippocampus. Cell Rep. 2021;37:110128.34965412
35. Tiihonen J Koskuvi M Lähteenvuo M Trontti K Ojansuu I Vaurio O Molecular signaling pathways underlying schizophrenia Schizophr Res 2021 232 33 41 10.1016/j.schres.2021.05.011 34010744
Tiihonen J, Koskuvi M, Lähteenvuo M, Trontti K, Ojansuu I, Vaurio O, et al. Molecular signaling pathways underlying schizophrenia. Schizophr Res. 2021;232:33–41.34010744
36. Koskuvi M Lehtonen Š Trontti K Keuters M Wu Y Koivisto H Contribution of astrocytes to familial risk and clinical manifestation of schizophrenia Glia 2022 70 650 60 10.1002/glia.24131 34936134
Koskuvi M, Lehtonen Š, Trontti K, Keuters M, Wu Y, Koivisto H, et al. Contribution of astrocytes to familial risk and clinical manifestation of schizophrenia. Glia. 2022;70:650–60.34936134
37. Shi J Levinson DF Duan J Sanders AR Zheng Y Pe’er I Common variants on chromosome 6p22.1 are associated with schizophrenia Nature 2009 460 753 7 10.1038/nature08192 19571809
Shi J, Levinson DF, Duan J, Sanders AR, Zheng Y, Pe’er I, et al. Common variants on chromosome 6p22.1 are associated with schizophrenia. Nature 2009;460:753–7.19571809
38. Qin S Yang C Huang W Du S Mai H Xiao J Sulforaphane attenuates microglia-mediated neuronal necroptosis through down-regulation of MAPK/NF-κB signaling pathways in LPS-activated BV-2 microglia Pharm Res 2018 133 218 35 10.1016/j.phrs.2018.01.014
Qin S, Yang C, Huang W, Du S, Mai H, Xiao J, et al. Sulforaphane attenuates microglia-mediated neuronal necroptosis through down-regulation of MAPK/NF-κB signaling pathways in LPS-activated BV-2 microglia. Pharm Res. 2018;133:218–35.
39. Wu Y Gao M Wu J Hu P Xu X Zhang Y Sulforaphane triggers a functional elongation of microglial process via the Akt signal J Nutr Biochem 2019 67 51 62 10.1016/j.jnutbio.2019.01.019 30856464
Wu Y, Gao M, Wu J, Hu P, Xu X, Zhang Y, et al. Sulforaphane triggers a functional elongation of microglial process via the Akt signal. J Nutr Biochem. 2019;67:51–62.30856464
40. Henry CJ Huang Y Wynne A Hanke M Himler J Bailey MT Minocycline attenuates lipopolysaccharide (LPS)-induced neuroinflammation, sickness behavior, and anhedonia J Neuroinflammation 2008 5 15 10.1186/1742-2094-5-15 18477398
Henry CJ, Huang Y, Wynne A, Hanke M, Himler J, Bailey MT, et al. Minocycline attenuates lipopolysaccharide (LPS)-induced neuroinflammation, sickness behavior, and anhedonia. J Neuroinflammation. 2008;5:15.18477398
41. Subedi L Lee J Yumnam S Ji E Kim S Anti-inflammatory effect of sulforaphane on LPS-activated microglia potentially through JNK/AP-1/NF-κB inhibition and Nrf2/HO-1 activation Cells 2019 8 194 10.3390/cells8020194 30813369
Subedi L, Lee J, Yumnam S, Ji E, Kim S. Anti-inflammatory effect of sulforaphane on LPS-activated microglia potentially through JNK/AP-1/NF-κB inhibition and Nrf2/HO-1 activation. Cells 2019;8:194.30813369
42. Hasselmann J Coburn MA England W Figueroa Velez DX Kiani Shabestari S Tu CH Development of a chimeric model to study and manipulate human microglia in vivo Neuron 2019 103 1016 33.e10 10.1016/j.neuron.2019.07.002 31375314
Hasselmann J, Coburn MA, England W, Figueroa Velez DX, Kiani Shabestari S, Tu CH, et al. Development of a chimeric model to study and manipulate human microglia in vivo. Neuron. 2019;103:1016–33.e10.31375314
43. Sinkus ML Adams CE Logel J Freedman R Leonard S Expression of immune genes on chromosome 6p21.3–22.1 in schizophrenia Brain Behav Immun 2013 32 51 62 10.1016/j.bbi.2013.01.087 23395714
Sinkus ML, Adams CE, Logel J, Freedman R, Leonard S. Expression of immune genes on chromosome 6p21.3–22.1 in schizophrenia. Brain Behav Immun. 2013;32:51–62.23395714
44. Norden DM Muccigrosso MM Godbout JP Microglial priming and enhanced reactivity to secondary insult in aging, and traumatic CNS injury, and neurodegenerative disease Neuropharmacology 2015 96 29 41 10.1016/j.neuropharm.2014.10.028 25445485
Norden DM, Muccigrosso MM, Godbout JP. Microglial priming and enhanced reactivity to secondary insult in aging, and traumatic CNS injury, and neurodegenerative disease. Neuropharmacology. 2015;96:29–41.25445485
45. Inta D Lang UE Borgwardt S Meyer-Lindenberg A Gass P Microglia activation and schizophrenia: lessons from the effects of minocycline on postnatal neurogenesis, neuronal survival and synaptic pruning Schizophr Bull 2016 43 sbw088 10.1093/schbul/sbw088
Inta D, Lang UE, Borgwardt S, Meyer-Lindenberg A, Gass P. Microglia activation and schizophrenia: lessons from the effects of minocycline on postnatal neurogenesis, neuronal survival and synaptic pruning. Schizophr Bull. 2016;43:sbw088.
46. Schetters STT Gomez-Nicola D Garcia-Vallejo JJ Van Kooyk Y Neuroinflammation: microglia and T cells get ready to tango Front Immunol 2018 8 1905 10.3389/fimmu.2017.01905 29422891
Schetters STT, Gomez-Nicola D, Garcia-Vallejo JJ, Van Kooyk Y. Neuroinflammation: microglia and T cells get ready to tango. Front Immunol. 2018;8:1905.29422891
47. Roche PA Furuta K The ins and outs of MHC class II-mediated antigen processing and presentation Nat Rev Immunol 2015 15 203 16 10.1038/nri3818 25720354
Roche PA, Furuta K. The ins and outs of MHC class II-mediated antigen processing and presentation. Nat Rev Immunol. 2015;15:203–16.25720354
48. Schlaaff K Dobrowolny H Frodl T Mawrin C Gos T Steiner J Increased densities of T and B lymphocytes indicate neuroinflammation in subgroups of schizophrenia and mood disorder patients Brain Behav Immun 2020 88 497 506 10.1016/j.bbi.2020.04.021 32283292
Schlaaff K, Dobrowolny H, Frodl T, Mawrin C, Gos T, Steiner J, et al. Increased densities of T and B lymphocytes indicate neuroinflammation in subgroups of schizophrenia and mood disorder patients. Brain Behav Immun. 2020;88:497–506.32283292
49. Busse S Busse M Schiltz K Bielau H Gos T Brisch R Different distribution patterns of lymphocytes and microglia in the hippocampus of patients with residual versus paranoid schizophrenia: further evidence for disease course-related immune alterations? Brain Behav Immun 2012 26 1273 9 10.1016/j.bbi.2012.08.005 22917959
Busse S, Busse M, Schiltz K, Bielau H, Gos T, Brisch R, et al. Different distribution patterns of lymphocytes and microglia in the hippocampus of patients with residual versus paranoid schizophrenia: further evidence for disease course-related immune alterations? Brain Behav Immun. 2012;26:1273–9.22917959
50. Murphy CE Weickert CS A new suspect in the unsolved case of neuroinflammation in schizophrenia Mol Psychiatry 2021 26 7105 6 10.1038/s41380-021-01225-8 34285346
Murphy CE, Weickert CS. A new suspect in the unsolved case of neuroinflammation in schizophrenia. Mol Psychiatry. 2021;26:7105–6.34285346
51. Corsi-Zuelli F Deakin B Impaired regulatory T cell control of astroglial overdrive and microglial pruning in schizophrenia Neurosci Biobehav Rev 2021 125 637 53 10.1016/j.neubiorev.2021.03.004 33713699
Corsi-Zuelli F, Deakin B. Impaired regulatory T cell control of astroglial overdrive and microglial pruning in schizophrenia. Neurosci Biobehav Rev. 2021;125:637–53.33713699
52. Gandal MJ Zhang P Hadjimichael E Walker RL Chen C Liu S Transcriptome-wide isoform-level dysregulation in ASD, schizophrenia, and bipolar disorder Science 2018 362 eaat8127 10.1126/science.aat8127 30545856
Gandal MJ, Zhang P, Hadjimichael E, Walker RL, Chen C, Liu S, et al. Transcriptome-wide isoform-level dysregulation in ASD, schizophrenia, and bipolar disorder. Science 2018;362:eaat8127.30545856
53. Crapser JD Arreola MA Tsourmas KI Green KN Microglia as hackers of the matrix: sculpting synapses and the extracellular space Cell Mol Immunol 2021 18 2472 88 10.1038/s41423-021-00751-3 34413489
Crapser JD, Arreola MA, Tsourmas KI, Green KN. Microglia as hackers of the matrix: sculpting synapses and the extracellular space. Cell Mol Immunol. 2021;18:2472–88.34413489
54. Strackeljan L Baczynska E Cangalaya C Baidoe-Ansah D Wlodarczyk J Kaushik R Microglia depletion-induced remodeling of extracellular matrix and excitatory synapses in the hippocampus of adult mice Cells 2021 10 1862 10.3390/cells10081862 34440631
Strackeljan L, Baczynska E, Cangalaya C, Baidoe-Ansah D, Wlodarczyk J, Kaushik R, et al. Microglia depletion-induced remodeling of extracellular matrix and excitatory synapses in the hippocampus of adult mice. Cells 2021;10:1862.34440631
55. Haw RTY Tong CK Yew A Lee HC Phillips JB Vidyadaran S A three-dimensional collagen construct to model lipopolysaccharide-induced activation of BV2 microglia J Neuroinflammation 2014 11 134 10.1186/1742-2094-11-134 25074682
Haw RTY, Tong CK, Yew A, Lee HC, Phillips JB, Vidyadaran S. A three-dimensional collagen construct to model lipopolysaccharide-induced activation of BV2 microglia. J Neuroinflammation. 2014;11:134.25074682
56. Zhang J Rong P Zhang L He H Zhou T Fan Y IL4-driven microglia modulate stress resilience through BDNF-dependent neurogenesis Sci Adv 2021 7 eabb9888 10.1126/sciadv.abb9888 33731342
Zhang J, Rong P, Zhang L, He H, Zhou T, Fan Y, et al. IL4-driven microglia modulate stress resilience through BDNF-dependent neurogenesis. Sci Adv. 2021;7:eabb9888.33731342
57. Sato K Effects of microglia on neurogenesis Glia 2015 63 1394 405 10.1002/glia.22858 26010551
Sato K. Effects of microglia on neurogenesis. Glia. 2015;63:1394–405.26010551
58. Gosselin D Skola D Coufal NG Holtman IR Schlachetzki JCM Sajti E An environment-dependent transcriptional network specifies human microglia identity Science 2017 356 eaal3222 10.1126/science.aal3222 28546318
Gosselin D, Skola D, Coufal NG, Holtman IR, Schlachetzki JCM, Sajti E, et al. An environment-dependent transcriptional network specifies human microglia identity. Science 2017;356:eaal3222.28546318
59. Popova G Soliman SS Kim CN Keefe MG Hennick KM Jain S Human microglia states are conserved across experimental models and regulate neural stem cell responses in chimeric organoids Cell Stem Cell 2021 28 2153 66.e6 10.1016/j.stem.2021.08.015 34536354
Popova G, Soliman SS, Kim CN, Keefe MG, Hennick KM, Jain S, et al. Human microglia states are conserved across experimental models and regulate neural stem cell responses in chimeric organoids. Cell Stem Cell. 2021;28:2153–66.e6.34536354
